secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2021-08-20T23:59:59+00:00
Accession:  0001193125-21-252071
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics appoints Julie Burgess as Chief Accounting Officer
----------------------------------------------------------------------

- Julie Burgess appointed Chief Accounting Officer, effective September 13, 2021.
- Annual base salary of $350,000, bonus up to 35%, and stock option for 135,000 shares.
- Burgess previously SVP Finance at Otonomy; brings over 25 years of experience.
- Dawn Giangiulio will cease as interim principal accounting officer but remain Controller.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/0001193125-21-252071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000119312521252071/d172325d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-252071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer